MEDCAPTAIN MEDICAL TECHNOLOGY CO., LTD. of Shenzhen at MEDICA 2022 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option

Submit your contact details

Provide your contact details to the exhibitor. Optionally, you may also add a personal message.

Please log in

You must be logged in to send the contact request.

An error has occurred

Please check your internet connection or try again later.

Message has been sent

Your message to the exhibitor was sent successfully.

Company news

Date

Topic

01 Aug 2022

Medcaptain Successfully Held the International Forum on Sepsis Diagnosis and Treatment

As a global public health emergency, Sepsis has attracted the attention of clinicians and basic researchers around the world. On April 9th, Medcaptain joined hands with authoritative experts in the field of critical care medicine from China and abroad to hold the International Forum on Sepsis Diagnosis and Treatment to facilitate the exchange of advanced treatment experience around the world.

During the Forum, Dr. Djillali ANNANE, Dean of the Faculty of Medicine, University of Paris Saclay-Campus of Versailles and Head of the Critical Care Department of Raymond Poincaré University Hospital (AP-HP), brought us a very exciting sharing about his study in COVID-19 and Sepsis. According to him, COVID 19 is not just an infection but viral sepsis. Sepsis and COVID-19 share common physiopathological pathways. The clinical benefit of corticosteroids has been shown for both sepsis and COVID-19. And other immunomodulatory approaches, including Anti-IL-6R and anti-IL-1R monoclonal antibodies, JAK inhibitors and complement inhibitors, have been used successfully for COVID-19.

Dr. Qingqing Dai, Director of the Department of Critical Care Medicine, Obstetrics & Gynecology Hospital of Fudan University, shared the importance of early diagnosis of Sepsis and the pros and cons of biomarkers of Sepsis commonly used in clinical practice. She said: “Mortality from Sepsis can be reduced through early recognition, each hour antibiotics are delayed in septic shock increases mortality by around 8%. In fact, diagnostic biomarkers can provide early information on Sepsis, and the use of a biomarker panel has the potential to provide greater information than the measurement of single markers alone. ” She also shared that new molecular techniques can provide faster and earlier information on Sepsis than the blood culture, but limited sensitivity prevents them from being widely used.

Meanwhile, a total of 200 expert participants joined the discussion actively and shared a lot of inspiration. The forum successfully shared the experience of sepsis diagnosis and treatment in different regions.

During the EuroMedLab in Munich, Germany, Medcaptain will present the latest in vitro diagnostic solutions, including fully automated chemiluminescent immunoassay testing system, next-generation blood grouping system and comprehensive molecular diagnostic solutions. Medcaptain is committed to making deeper inroads into the European premium market with leading-edge products and solutions. With an ongoing commitment to innovation and technological advancement, Medcaptain will also continue to forge ahead to further advance healthcare standards and efficiency worldwide.

More Less

26 Jul 2022

Medcaptain Exhibits at 2022 AACC with Latest In-vitro Diagnostics Innovations

On July 26-28, Medcaptain made a striking appearance with a series of main In-vitro Diagnostics products and solutions at the 74th American Association for Clinical Chemistry Annual Scientific Meeting and Clinical Laboratory Exposition (2022 AACC), held at the McCormick Place Convention Center in Chicago.

Being the world's largest conference of the in-vitro diagnostic industry, the AACC has become one of the most important international academic conferences in the field of clinical testing worldwide and has a significant international influence, attracting over 20,000 international medical professionals and medical device entrepreneurs from over 100 countries worldwide each year.

At 2022 AACC, Medcaptain showcased the cutting-edge science and technology shaping the future of laboratory medicine, including main products like the Fully-automated Chemiluminescence Immunoassay System, Real-time PCR System, Thromboelastography Analyzer, and Fully Automatic Blood Grouping Analyzer, covering coagulation, chemiluminescence, blood typing and molecular diagnostics, as well as comprehensive test items. It has attracted many visitors from around the world, capturing the much-needed disease testing business opportunities.

Medcaptain’s latest in-vitro diagnostics innovations enable clinical laboratories greater flexibility and assurance as they respond to new and existing diagnostic challenges. By minimizing hands-on time, reducing time-to-results, and improving analytical performance, Medcaptain, together with clinical users, is working toward improving patient outcomes.

Over years of operation and development, Medcaptain has won a considerable number of loyal customers in the whole world with its high-quality products and services. In the future, Medcaptain will keep advancing to meet the clinical needs, sharing more medical technologies and providing better healthcare products and solutions for society.

More Less

02 Apr 2022

Medcaptain Will Exhibit at EuroMedLab!

As Europe gradually reopens from the epidemic, the 24th IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine (EuroMedLab 2021) will be held in Munich, Germany from April 10th to 14th.

EuroMedLab is jointly organized by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) and the German Society for Clinical Chemistry and Laboratory Medicine (DGKL). Held every 2 years, the Congress is an important platform for laboratory medicine experts from around the world to share innovative technologies in laboratory medicine.

As one of the most mature regions in the development of laboratory medicine in the world, Europe is home to the world's leading experts and technological concepts in laboratory medicine. At this event, Medcaptain Medical Technology Co., Ltd. (hereinafter referred to as Medcaptain) will present innovative products including the fully-automated chemiluminescence immunoassay system, the new generation of blood grouping system and molecular diagnostic solutions, as well as comprehensive test items. We look forward to welcoming more industry experts and scholars to visit us at booth 265!

Meanwhile, Medcaptain has also been actively involved in promoting academic exchanges between China and abroad. As a global public health emergency, sepsis is of great concern to clinicians and basic researchers due to its high morbidity, mortality and medical costs. During the conference, Medcaptain will also join hands with authoritative experts from China and Europe to hold the International Forum on Sepsis Diagnosis and Treatment, which will provide an academic exchange platform to share clinical treatment protocols and experiences with medical professionals around the world.

More Less

Please log in

You must be logged in to use matchmaking